Rs2058539 and rs10953505 visfatin gene polymorphisms their plasma concentrations and occurrence of overweight and obesity among patients reporting to primary healthcare clinic
More details
Hide details
Katedra i Klinika Chorób Wewnętrznych, Diabetologii i Nefrologii Śląskiego Uniwersytetu Medycznego w Katowicach
Corresponding author
Władysław Grzeszczak   

Katedra i Klinika Chorób Wewnętrznych, Diabetologii i Nefrologii Śląskiego Uniwersytetu Medycznego w Katowicach, 41-800 Zabrze, ul. 3. Maja 13-15
Ann. Acad. Med. Siles. 2015;69:184-190
Visfatin is a newly discovered adipocytokine displaying insulino-mimetic properties. The role of the investigated polymorphisms in visfatin coding genes and their blood plasma levels in the development of increased body mass remains controversial.

The aim of the study is to assess a potential correlation between selected visfatin gene polymorphisms, their plasma concentration, and the prevalence of overweight and obesity in patients reporting to a primary healthcare clinic.

Materials and methods:
The study included 476 adult patients from southern regions of Poland reporting to a primary healthcare clinic. The subjects were divided into 3 groups based on the value of waist circumference. The genotyping of visfatin gene polymorphisms (rs2058539 and rs10953505) was conducted with fluorescently marked probes by using predesigned single nucleotide polymorphisms assessment sets – TaqMan Pre-designed SNP Genotyping Assay (Applied Biosystems). The visfatin plasma levels were established using the ELISA method.

The study showed no correlation between visfatin plasma concentration and the examined gene polymorphisms. A statistically relevant difference in the occurrence of the rs2058539 polymorphism in obese persons in contrast to those with normal waist girth, was initially noted. An “A” allele of the rs2058539 polymorphism was significantly more often present in obese patients.

Based on the carried-out research, it can be concluded that the rs2058539 polymorphism of the visfatin gene can take part in the pathogenesis of excessive body weight increase. There is no correlation between the studied polymorphisms and visfatin plasma concentration.

World Health Organization: The challenge of obesity in the WHO European Region. Fact sheet EURO 2005; 13.
Samal B., Sun Y., Stearns G., Xie S., Suggs C., McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell. Biol. 1994; 14: 1431–1437.
Kitani T., Okuno S., Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett 2003; 544: 74–78.
Sommer G., Garten A., Petzold S., Beck-Sickinger A.G., Blüher M., Stumvoll M., Fasshauer M. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clin. Sci. (Lond.) 2008; 115: 13–23.
Adeghate E. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr. Med. Chem. 2008; 15: 1851–1862.
Moschen A.R., Kaser A., Enrich B., Mosheimer B., Theurl M., Niederegger H., Tilg H. Visfatin, anadipocytokine with proinflammatory and immunomodulating properties. J. Immunol. 2007; 178: 1748–1758.
Van Beijnum J.R., Moerkerk P.T., Gerbers A.J. De Bruïne A.P., Arends J.W., Hoogenboom H.R., Hufton S.E. Target validation for genomics using pep-tide-specific phage antibodies: a study of five gene products over-expressed in colorectal cancer. Int. J. Cancer 2002; 101: 118–127.
Adya R., Tan B.K., Punn A. Chen J., Randeva H.S. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc. Res. 2008; 78: 356–365.
Oita R.C., Ferdinando D., Wilson S., Bunce C., Mazzatti D.J. Visfatin induces oxidative stress in differentiated C2C12 myotubes in an Akt- and MAPK-independent, NfkB-dependent manner. Pflugers Arch. 2010; 459: 619–630.
Vazquez-Vela M.E., Torres N., Tovar A.R. White adipose tissue as endocrine organ and its role in obesity. Arch. Med. Res. 2008; 39(8): 715–728.
Zwirska-Korczala K., Sodowski K., Konturek S.J., Kuka D., Kukla M., Brzozowski T., Cnota W., Woźniak-Grygiel E., Jaworek J., Bułdak R., Rybus-Kalinowska B., Fryczowski M. Postprandial response of ghrelin and PYY and indices of low-grade chronic inflammation in lean young women with polycystic ovary syndrome. J. Physiol. Pharmacol. 2008; 59(supl. 2): 161–178.
Source: Applied Biosystems 7300/7500/7500 Fast Real – Time PCR System Allelic Discrimination Getting Started Guide.
Modan M., Karasik M., Halkin H., Fuchs Z., Lusky A., Shitrit A., Modan B. Effect of past and present body mass index on prevalence of glucose intolerance and type 2 (non-insulin-dependent) diabetes and on insulin response. The Israel study of glucose intolerance, obesity and hypertension. Diabetologia 1986; 29: 82–89.
Ferrannini E., Camastra S. Relationship between impaired glucose tolerance, non-insulin dependent diabetes mellitus and obesity. Eur. J. Clin. Invest. 1998; 28(suppl. 2): 3–7.
Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., Matsuki Y., Murakami M., Ichisaka T., Murakami H., Watanabe E., Takagi T., Akiyoshi M., Ohtsubo T., Kihara S., Yamashita S., Makishima M., Funahashi T., Yamanaka S., Hiramatsu R., Matsuzawa Y., Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426–430.
Varma V., Yao-Borengasser A., Rasouli N., Bodles A.M., Phanavanh B., Lee M.J., Starks T., Kern L.M., Spencer H.J. 3rd, McGehee R.E. Jr, Fried S.K., Kern P.A. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J. Clin. Endocrinol. Metab. 2007; 92: 666–672.
Jian W.X., Luo T.H., Gu Y.Y., Zhang H.L., Zheng S., Dai M., Han J.F., Zhao Y., Li G., Luo M. The visfatin gene is associated with glucose and lipid metabolism in a Chinese population. Diabet. Med. 2006; 23: 967–973.
Liu S.W., Qiao S.B., Yuan J.S., Liu D.Q. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin. Endocrinol. (Oxf.). 2009; 71: 202–207.
Bailey S.D., Loredo-Osti J.C., Lepage P., Faith J., Fontaine J., Desbiens K.M., Hudson T.J., Bouchard C., Gaudet D., Pérusse L., Vohl M.C., Engert J.C. Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. Diabetes 2006; 55: 2896–2902.
Bottcher Y., Teupser D., Enigk B., Berndt J., Klöting N., Schön M.R., Thiery J., Blüher M., Stumvoll M., Kovacs P. Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans. J. Clin. Endocrinol. Metab. 2006; 91: 2725–2731.
Johansson L.M., Johansson L.E., Ridderstrale M. The visfatin (PBEF1) G-948T gene polymorphism is associated with increased high-density lipoprotein cholesterol in obese subjects. Metabolism. 2008; 57(11): 1558–1562.
Journals System - logo
Scroll to top